This paper introduces a new endometrial cancer cell line, HCI-EC-23, which responds to estrogen and progesterone, and shows it has similar estrogen-responsive gene regulation to Ishikawa cells.

bioRxiv · Aug 25, 2022Cancer Biology

Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer

Z. Blanchard, C. M. Rush, S. Arnesen, J. M. Vahrenkamp, A. C. Rodriguez, E. A. Jarboe, C. Brown, M. E. K. Chang, M. R. Flory, H. Mohammed, K. Modzelewska, D. H. Lum, J. Gertz

This study investigates ER mutations in endometrial cancer, showing they alter gene expression and promote cancer phenotypes, and identifies potential therapeutic targets.

bioRxiv · Jun 13, 2022Cancer Biology

Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and through secondary effects

S. Arnesen, Z. Blanchard, M. M. Williams, K. C. Berrett, Z. Li, S. Oesterreich, J. K. Richer, J. Gertz

This study shows that ER mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects, not just ligand independence.

bioRxiv · Apr 8, 2020Cancer Biology

Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer

Z. Blanchard, J. M. Vahrenkamp, K. C. Berrett, S. Arnesen, J. Gertz

This study investigates estrogen-independent actions of the D538G ESR1 mutation in endometrial cancer, showing altered genomic binding, gene expression, and chromatin accessibility compared to wildtype ESR1.

bioRxiv · Jul 3, 2019Cancer Biology